ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	2.49T
Revenue (ttm)	318.32B
Net Income (ttm)	36.89B
Shares Out	20.70M
EPS (ttm)	1,795.21
PE Ratio	67.07
Forward PE	40.28
Dividend	500.00 (0.41%)
Ex-Dividend Date	Dec 27, 2024

Volume	140,993
Average Volume	218,294
Open	120,400
Previous Close	120,400
Day's Range	117,800 - 121,200
52-Week Range	66,600 - 134,000
Beta	0.25
RSI	49.70
Earnings Date	Feb 5, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.